ECSP056128A - Fluoro y trifluoroalquil que contienen inhibidores de producción de beta amiloide de sulfonamida heterociclico y derivados del mismo - Google Patents

Fluoro y trifluoroalquil que contienen inhibidores de producción de beta amiloide de sulfonamida heterociclico y derivados del mismo

Info

Publication number
ECSP056128A
ECSP056128A EC2005006128A ECSP056128A ECSP056128A EC SP056128 A ECSP056128 A EC SP056128A EC 2005006128 A EC2005006128 A EC 2005006128A EC SP056128 A ECSP056128 A EC SP056128A EC SP056128 A ECSP056128 A EC SP056128A
Authority
EC
Ecuador
Prior art keywords
group
substitute
low alkyl
hydrogen
phenyl
Prior art date
Application number
EC2005006128A
Other languages
English (en)
Inventor
Derek Cecil Cole
Anthony Frank Kreft
Lynn Resnick
Scott Christian Mayer
George Diamantidis
Tingzhong Wang
Rocco John Galante
Molly Hoke
Boyd Lynn Harrison
Minsheng Zhang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP056128A publication Critical patent/ECSP056128A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de Fórmula (I), En donde: T es seleccionada del grupo consistente de CHO, COR8 y C(OH)R1R2; R1 R2 son independientemente seleccionadas de un grupo consistente de hidrogeno, alquil bajo, sustituto de alquil bajo, CF3, alquenil, alquenil sustituto, alquinil, y alquinil sustituto; R3 es seleccionado de un grupo consistente de hidrogeno, alquil bajo y sustituto de alquil bajo: R4 es seleccionado de un grupo consistente de (CF3)n alquil, (CF3)n (susituto de alquil), (CF3) alquil (sustituto de fenil), Y (F)n cicloalquil; n = 1-3; R5 es seleccionado de un grupo consistente de hidrogeno, halógeno, CF3, dieno fusionado a Y cuando Y=C, y dieno sustituído fusionado cuando Y=C; W, Y y Z son independientemente seleccionados de un grupo consistente de C, CR6, y N con la provisión de que por lo menos W o Y o Z debe ser C; R6 es seleccionado de un grupo consistente de hidrogeno, halógeno, alquil bajo y sustitutos de alquil bajo; X es seleccionado de un grupo consistente de O, S, SO2 y NR7; R7 es seleccionado de un grupo consistente de hidrogeno, alquil bajo, sustituto de alquil bajo, benzil, sustituto de benzil, fenil, sustituto de fenil; y R8 es seleccionado de un grupo consistente de alquil bajo, CF3, fenil y sustituto de fenil. Métodos de preparación y usos de estos compuestos inhibidores de producción beta amiloide, para el tratamiento de enfermedad de Alzheimer y Síndrome de Down.
EC2005006128A 2003-03-31 2005-10-28 Fluoro y trifluoroalquil que contienen inhibidores de producción de beta amiloide de sulfonamida heterociclico y derivados del mismo ECSP056128A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45922803P 2003-03-31 2003-03-31

Publications (1)

Publication Number Publication Date
ECSP056128A true ECSP056128A (es) 2006-03-01

Family

ID=33299665

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006128A ECSP056128A (es) 2003-03-31 2005-10-28 Fluoro y trifluoroalquil que contienen inhibidores de producción de beta amiloide de sulfonamida heterociclico y derivados del mismo

Country Status (22)

Country Link
US (3) US7300951B2 (es)
EP (1) EP1608638A1 (es)
JP (1) JP2006522126A (es)
KR (1) KR20060002908A (es)
CN (2) CN1780829B (es)
AR (1) AR043940A1 (es)
AU (1) AU2004230844B2 (es)
BR (1) BRPI0408962A (es)
CA (1) CA2517155A1 (es)
CL (1) CL2004000647A1 (es)
CO (1) CO5640049A2 (es)
CR (1) CR7951A (es)
EC (1) ECSP056128A (es)
MX (1) MXPA05010368A (es)
NO (1) NO20054263L (es)
NZ (1) NZ542468A (es)
RU (1) RU2342374C2 (es)
SG (1) SG167669A1 (es)
TW (1) TWI336698B (es)
UA (1) UA82093C2 (es)
WO (1) WO2004092155A1 (es)
ZA (1) ZA200507896B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517892A (ja) * 2000-12-13 2004-06-17 ワイス β−アミロイド産生の複素環スルホンアミド阻害剤
CA2471099C (en) * 2001-12-20 2011-04-12 Bristol-Myers Squibb Company .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors
KR20050010882A (ko) * 2002-06-11 2005-01-28 와이어쓰 베타 아밀로이드 생산의 치환 페닐술폰아미드 저해제
KR20060002908A (ko) * 2003-03-31 2006-01-09 와이어쓰 베타 아밀로이드 생산 억제제인 플루오로- 및트리플루오로알킬-함유 헤테로사이클릭 설폰아미드 및 이의유도체
DE602005016775D1 (de) * 2004-01-16 2009-11-05 Wyeth Corp Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
AR059517A1 (es) * 2006-02-17 2008-04-09 Wyeth Corp N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
EP1984321A1 (en) * 2006-02-17 2008-10-29 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
CN101472877A (zh) * 2006-04-21 2009-07-01 惠氏公司 制备手性纯氨基醇中间体、其衍生物及其用途
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
JP2010509235A (ja) * 2006-11-03 2010-03-25 ノースウェスタン ユニバーシティ 多発性硬化症の治療
TW200911778A (en) * 2007-07-16 2009-03-16 Wyeth Corp Process for the preparation of trifluoroalkyl-phenyl and heterocyclic sulfonamides
JP2010533723A (ja) * 2007-07-16 2010-10-28 ワイス・エルエルシー βアミロイド生成の阻害剤
PA8789801A1 (es) * 2007-07-16 2009-02-09 Wyeth Corp Procesos e intermadiarios para la preparacion de compuestos de silfonamida heterocíclica
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
TW200934482A (en) * 2008-01-11 2009-08-16 Wyeth Corp Compositions containing o-sulfate and o-phosphate containing aryl sulfonamide derivatives useful as β -amyloid inhibitors
WO2009137657A1 (en) * 2008-05-08 2009-11-12 Bristol-Myers Squibb Company 2-aryl glycinamide derivatives
US8992783B2 (en) 2008-09-05 2015-03-31 Max-Planck-Gessellschaft zur förderung der Wissenschaften e.V. Process for enantioseparation of chiral systems with compound formation using two subsequent crystallization steps
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US20110071199A1 (en) * 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
US7977362B2 (en) * 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
WO2011084503A1 (en) * 2009-12-16 2011-07-14 North Carolina Central University Phenoxy thiophene sulfonamides and their use in the treatment of neurodegenerative diseases
US9223209B2 (en) * 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing photoresist compositions and methods of use
US9223217B2 (en) 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing topcoat and photoresist additive compositions and methods of use
WO2011112858A1 (en) * 2010-03-10 2011-09-15 North Carolina Central University Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
US20150209367A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye & Ear Infirmary Treating Hearing Loss
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
US11370823B2 (en) 2014-10-29 2022-06-28 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
JP6840774B2 (ja) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション 肺上皮エンジニアリングにおけるヒト気道幹細胞
WO2019148067A1 (en) 2018-01-26 2019-08-01 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
EP4299062A1 (en) 2022-06-30 2024-01-03 Vilnius University Inhibition of protein amyloid aggregation using fluorinated benzenesulfonamides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0510700A3 (en) 1991-04-26 1992-12-16 Takeda Chemical Industries, Ltd. Azole compounds, their production and use
GB9110722D0 (en) 1991-05-17 1991-07-10 Fujisawa Pharmaceutical Co Amine derivatives
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
NZ264143A (en) 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
US5519040A (en) 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
ATE377006T1 (de) 1995-11-28 2007-11-15 Cephalon Inc Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer
JP2000515153A (ja) 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
US5703129A (en) 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
US5985930A (en) 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
TR199901132T2 (xx) 1996-11-22 1999-08-23 Elan Pharmaceuticals, Inc. N-(aril/heteoaril) amino asit t�revleri, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler.
DE19650196A1 (de) 1996-12-04 1998-06-10 Bayer Ag Thienylsulfonylamino(thio)carbonylverbindungen
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
AU765203B2 (en) 1999-04-19 2003-09-11 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1222176A1 (en) 1999-10-08 2002-07-17 Bristol-Myers Squibb Pharma Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION
WO2001070677A1 (en) 2000-03-20 2001-09-27 Merck Sharp & Dohme Limited Sulphonamido-substituted bridged bicycloalkyl derivatives
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
JP2004517892A (ja) 2000-12-13 2004-06-17 ワイス β−アミロイド産生の複素環スルホンアミド阻害剤
WO2003050062A2 (en) 2001-12-11 2003-06-19 Wyeth PRODUCTION OF CHIRALLY PURE α-AMINO ACIDS ADN N-SULFONYL α-AMINO ACIDS
BR0214863A (pt) 2001-12-11 2004-12-14 Wyeth Corp Processo para a sìntese de beta-aminoálcoois quiralmente puros
KR20050010882A (ko) 2002-06-11 2005-01-28 와이어쓰 베타 아밀로이드 생산의 치환 페닐술폰아미드 저해제
KR20060002908A (ko) 2003-03-31 2006-01-09 와이어쓰 베타 아밀로이드 생산 억제제인 플루오로- 및트리플루오로알킬-함유 헤테로사이클릭 설폰아미드 및 이의유도체
DE602005016775D1 (de) 2004-01-16 2009-11-05 Wyeth Corp Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
AR059517A1 (es) * 2006-02-17 2008-04-09 Wyeth Corp N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
EP1984321A1 (en) * 2006-02-17 2008-10-29 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
CN101472877A (zh) * 2006-04-21 2009-07-01 惠氏公司 制备手性纯氨基醇中间体、其衍生物及其用途
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
JP2010533723A (ja) * 2007-07-16 2010-10-28 ワイス・エルエルシー βアミロイド生成の阻害剤
PA8789801A1 (es) * 2007-07-16 2009-02-09 Wyeth Corp Procesos e intermadiarios para la preparacion de compuestos de silfonamida heterocíclica
TW200911778A (en) * 2007-07-16 2009-03-16 Wyeth Corp Process for the preparation of trifluoroalkyl-phenyl and heterocyclic sulfonamides

Also Published As

Publication number Publication date
UA82093C2 (uk) 2008-03-11
CR7951A (es) 2008-10-29
US7547725B2 (en) 2009-06-16
US7858658B2 (en) 2010-12-28
AU2004230844B2 (en) 2010-12-09
CA2517155A1 (en) 2004-10-28
AU2004230844A1 (en) 2004-10-28
US7300951B2 (en) 2007-11-27
NZ542468A (en) 2009-01-31
CL2004000647A1 (es) 2005-02-04
KR20060002908A (ko) 2006-01-09
CN101274926A (zh) 2008-10-01
NO20054263D0 (no) 2005-09-15
WO2004092155A1 (en) 2004-10-28
ZA200507896B (en) 2007-03-28
AR043940A1 (es) 2005-08-17
RU2342374C2 (ru) 2008-12-27
SG167669A1 (en) 2011-01-28
CN1780829A (zh) 2006-05-31
TW200504047A (en) 2005-02-01
US20090227667A1 (en) 2009-09-10
RU2005133434A (ru) 2006-07-10
MXPA05010368A (es) 2005-11-17
TWI336698B (en) 2011-02-01
US20070254929A1 (en) 2007-11-01
US20040198778A1 (en) 2004-10-07
BRPI0408962A (pt) 2006-04-04
NO20054263L (no) 2005-12-14
CN1780829B (zh) 2010-12-29
JP2006522126A (ja) 2006-09-28
EP1608638A1 (en) 2005-12-28
CO5640049A2 (es) 2006-05-31

Similar Documents

Publication Publication Date Title
ECSP056128A (es) Fluoro y trifluoroalquil que contienen inhibidores de producción de beta amiloide de sulfonamida heterociclico y derivados del mismo
SV2006002103A (es) Compuestos de aril- o heteroarilamida ortosustituidos ref. pc32242a
PA8610801A1 (es) Compuestos de aril o heteroaril amida
IS2598B (is) Þíenópýrimidíndíón og notkun þeirra í mótun sjálfnæmissjúkdóma
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
CO4700455A1 (es) Derivados tetraciclicos y proceso para su preparacion
CY1105957T1 (el) Χρηση οιστρογονων ενωσεων σε συνδυασμο με ενωσεις προγεστογονου (progestogen) σε θepαπεια ορμονικης αντικαταστασης
SE9904176D0 (sv) New use
CO5560573A2 (es) Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
ES2092113T3 (es) Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
AR048289A1 (es) Eteres de anillos imidazo sulfona sustituidos.
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
AR035451A1 (es) Derivados de beta-carbolina, su uso para la fabricacion de un medicamento para el tratamiento de la depresion, ansiedad y desordenes bipolares, una composicion farmaceutica y una combinacion.
CO4700291A1 (es) Compuestos quimicos
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
MX9207215A (es) Derivados de acidos guanidino-alquil-1,1-bis-fosfonicos, procedimientos para su preparacion y su utilizacion.
UY28647A1 (es) Compuestos de amida del ácido 3-amino-tieno(2,3-b)piridin-2-carboxílico sustituido y procedimientos para su preparación y sus usos
DE502004002171D1 (de) Verwendung von 2-amino-2h-chinazolin-derivaten zur herstellung von therapeutischen mitteln
ES2060127T3 (es) Halogenoalquilfenil-alcoholes-cetonas y sus hidratos.
AR041898A1 (es) Derivados de 4(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor y desordenes gastrointestinales
ES2054811T3 (es) Derivados de tetrahidroisoquinolin-2-ilo como antagonistas de tromboxano a2.
AR036204A1 (es) Proceso para la produccion de quinazolinas y compuestos utiles en dicho proceso
ES2028838T3 (es) Procedimiento para la obtencion de nuevos derivados de 4,5-hidro-oxazoles.
ES2155433T3 (es) Compuestos de 7-acil-3-(carbamoiloxi substituido) cefem, su utilizacion y procedimiento para su fabricacion.